Home / Peptides / CJC-1295
Research only — not approved

CJC-1295

A long-acting GHRH analog — and why “with DAC” vs “no DAC” is the whole story

Research compound

CJC-1295 is not approved by the FDA for any indication. Human safety and long-term effects have not been established in completed trials. Anything sold under this name is an unregulated research chemical. This page is educational, not medical advice.

Class

GHRH analog

Half-Life

Days (with DAC)

FDA Status

Not approved

What CJC-1295 is

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH) — specifically a modified version of the active GRF(1-29) fragment. Like natural GHRH, it signals the pituitary to release growth hormone. Where ipamorelin works through the ghrelin receptor, CJC-1295 works through the GHRH receptor, which is why the two are often discussed (and marketed) together.

The DAC distinction that matters

“CJC-1295” is sold in two very different forms, and conflating them is the most common source of confusion:

  • With DAC (Drug Affinity Complex): a modification lets it bind to albumin in the blood, extending its half-life to the order of days and producing a sustained rise in GH and IGF-1.
  • Without DAC (often sold as “modified GRF 1-29”): short-acting, cleared in minutes to hours, producing brief GH pulses closer to the body's natural pattern.

Early clinical pharmacology of the DAC form (Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006) documented sustained increases in GH and IGF-1 in healthy adults after single doses. That is a pharmacology finding — it shows the molecule does what it's designed to do — not evidence of a health benefit or of long-term safety.

What we can and can’t say

Not established

  • Any specific clinical benefit (fat loss, muscle, recovery, anti-aging) from chronically elevated GH/IGF-1 via this route.
  • Long-term safety — sustained IGF-1 elevation is exactly the kind of effect long trials exist to scrutinize.
  • The identity, dose, and sterility of grey-market product (and whether “CJC-1295” in a vial is the DAC or no-DAC form at all).

CJC-1295 is commonly stacked with ipamorelin in grey-market protocols. Combining a GHRH analog with a ghrelin-receptor agonist is a marketing convention, not an approved or trial-validated regimen.

If you're tracking a protocol, do it privately and honestly. Jabbit is an ad-free injection log — no data selling, no hype.

Download on App Store